Will the ESC Congress 2026 publish or announce at least one late-breaking randomized controlled trial result involving a GLP-1 receptor agonist for a cardiovascular endpoint during 2026-08-28 through 2026-08-31, as reported in an official ESC press release or session listing by 2026-09-01?

Resolves YES if ESC Congress 2026 publishes or presents at least one late-breaking randomized controlled trial result with a GLP-1 receptor agonist (e.g., semaglutide, tirzepatide, or similar) as a primary treatment arm evaluating a cardiovascular efficacy or safety endpoint, as reported in an official ESC press release or session listing by 2026-09-01. Resolves NO if no such trial is presented. Source: ESC Congress 2026 official press releases and scientific programme